Welcome to ELISHA.
 

This is the Technical Web Site of ELISHA Systems Ltd.


ELISHA was the acronym of the EU project funded under the Nanotechnology Theme of Framework 6.  The project was completed on 30th June 2007 and the technology is being commercialised by ELISHA Systems Ltd., a new SME based in the UK.

 

 

Latest News:  27th - 30th May 2014:  ELISHA Systems Ltd will be at the World Congress on Biosensors in Melbourne, Australia presenting results to detect and quantify MRSA in  field environments.

More information in 'Latest News' below.

 

 

Main Contacts for ELISHA Systems Ltd:


Technical Enquiries

Dr Tim Gibson           Telephone 01924 829560 

                                  e-mail  t.d.gibson@leeds.ac.uk

 

Business Enquiries

Dr Graham Johnson   Telephone 01298 70891

                                  e-mail  graham.johnson@uniscan.com

 

Registered Address

Pinewood Court
Larkwood way
Tytherington Business Park
Macclesfield
Cheshire
SK10 2XR
 
Company number  6142403

ELISHA Systems Ltd is developing Biochips and Point-of-Care Instrumentation based on the ELISHA immunosensor technology.

 

Since 2008, ELISHA Systems Ltd has been developing the ELISHA technology to be commercially viable.    The basic technology comprises disposable single measurement biochips and an electrochemical reader that is being designed to be a Point-of-Care device. 

Biochips can be configured in different ways:

 

1)      Single analyte configuration using 2 working electrodes to generate the specific signal and to correct for non-specific binding

2)      Multiple analyte configuration using multiple working electrodes to detect a number of target analytes from a single sample.

 

The analytical sequence to measure target analytes is essentially the same for each type of biochip.

 

       Add sample to biochip incubate for several minutes read concentration.

 

The incubation time depends on the target and concentration range of the target analyte, but it is of the order of 5 to 20 minutes for most target analytes measured to date.

 

The development has demonstrated the feasibility of the antibody based biochips to detect many more analytes in a wide range of sample matrices.   Some examples are given below.

 

ANALYTE                           MATRIX                                  SENSITIVITY

Meningococcus                   Whole human blood                 10 cells in 100l blood

Myoglobin                          Human serum                         10 picogrammes per ml

Fluoroquinoline antibiotics    Bovine milk                            1 nanogramme per ml  

MRSA                                PBS / non-ionic detergent        10 cells per ml

 

To date most protein and carbohydrate biomarkers are quantifiable down to picogramme per ml levels in 20 minutes. Most bacterial samples seem to have a detection limit of 10 cells per ml or 10 cells per sample (e.g. for the miningococcus  example, 100l of whole blood containing 100cells per ml gave a consistently measurable response).   Recently viruses have been detected and quantified directly using a virus antibody.  In addition target analytes have been detected and quantified in neat human saliva and neat human urine working with third party clients.

 

ELISHA Systems Ltd has World-wide patent protection in the area of AC Impedance interrogation of protein biochips and has IP in an alternative electrochemical detection technique developed in the ELISHA project.

 

ELISHA Systems Ltd is looking to discuss potential collaborations with interested third parties who have analyte panels they would like to transfer onto the ELISHA platform. Please contact Dr Tim Gibson or Dr Graham Johnson using the contact details above.

 

Latest News

17/Feb/2014

ELISHA Systems Ltd to present results for MRSA detection at the World Congress on Biosensors 2014

Specific detection of MRSA using a novel phage lysin mediated biosensor has been successfully demonstrated and the TSB sponsored project PROMPT-Plus is proceeding to trial the biosensors

...read more


09/Apr/2013

ELISHA Systems Ltd Leading TSB Biomedical Catalyst Project to Detect MRSA

ELISHA Systems Ltd has been successful in recieving funding from the Technology Strategy Board's Biomedical Catalyst Initiative. The project PROMPT-Plus is based on the successful feasibility project PROMPT, where MRSA was specifically detected using an internal protein biomarker by antibody based biosensors coupled with bacteriophage lysin technology.

...read more


27/Mar/2012

ELISHA Systems Ltd is part of a TSB funded project in plastic electronics

Plastic electronics is an area that is developing rapidly and holds strong promises for the development of new electrodes in the biosensor field. ELISHA Systems Ltd is working in this TSB project to evaluate the new electrode technology in the development of antibody based biosensors. Target analytes are Neisseria gonorrhoea and Chlamydia.

...read more